2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 416

Prospective, Standardized, Longitudinal Assessment Reveals Higher Prevalence of Extracutaneous Manifestations in a Pediatric Localized Scleroderma Cohort

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 403

Proteinuria in Childhood Onset Lupus Nephritis: When Does It Go Away ?

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 21

Pseudostarvation Using the AMPK Activator Metformin Downregulates Inflammation in Rheumatoid Arthritis Synovial Tissue

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster I

9:00AM-11:00AM: Abstract Number: 252

Pyrin (MEFV) Mutations in New York: Revisiting the Mount Sinai Experience with Periodic Fever and Serositis

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 472

Quality Assessment in Clinical Management of Patients with Rheumatoid Arthritis. Are We Using the “Treat to Target” Strategy?

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 258

Quality of Life Changes with Canakinumab Therapy in Adults with Colchicine Resistant FMF

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 694

Quality of Life in Patients with Active Peripheral Spa Is Similarly Impaired As in Other Rheumatic Diseases and Influenced By Disease Activity but Not Disease Duration

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

9:00AM-11:00AM: Abstract Number: 539

Quantification of T-Cell Receptor Excision Circles (TREC) from Peripheral Blood in Patients with Inflammatory Polyarthritis of Recent Onset (EPA): Association with Radiographic Joint Damage

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 375

RA May Not Confer Addition Risk of Osteoporosis in Male Patients – Results of Cohort Analysis and Literature Review

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 457

RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 528

RA33 Challenges the Paradigm of Autoantigen Selection in Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 484

Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 401

Racial and Ethnic Disparities in Depression Diagnosis and Treatment for Adolescents with SLE: Analysis of a National Medicaid Sample

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster I: Lupus, Scleroderma, JDMS

9:00AM-11:00AM: Abstract Number: 340

Radiographic Assessment of Hand Osteoarthritis – the Role of Oblique View Images

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 462

Radiographic Progression in Patients with Early Rheumatoid Arthritis Has Not Become Milder over the Past Decades

Rheumatoid Arthritis - Clinical Aspects Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].